Buyers in Short Supply - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Buyers in Short Supply
Global pharmaceutical companies could have a problem getting rid of redundant facilities.

Pharmaceutical Technology
Volume 10, Issue 34, pp. 82-84

The Riverside buyback highlights another problem for bio/pharmaceutical companies trying to sell or divest redundant facilities: namely, that large legacy pharmaceutical manufacturing sites may not be financially viable for a CMO to operate, especially in today's business environment. Large sites such as Riverside have a lot of fixed assets that must be maintained and operated whether or not they are being utilized. Cherokee had to maintain a 340-acre site that includes three commercial-scale synthesis plants, two good-manufacturing-practice kilo laboratories, a fermentation facility with 43 fermentors, 10 warehouses, and laboratory space; little of that capacity was utilized. At almost $100 million in revenues, Cherokee would have been considered a substantially sized API manufacturer, but the cost of maintaining all of these facilities probably overwhelmed the revenue generated by the legacy Merck contracts.

Cherokee is certainly not the first pharma-to-CMO deal not to work out well. Keata Pharma, a Canadian dose CMO, filed for bankruptcy within a year of buying its facility in Arnprior, Ontario, from Pfizer. Inyx, a UK-based CMO, went into receivership soon after buying a facility in Puerto Rico from sanofi-aventis (Paris); sanofi-aventis had to retake the facility much like Merck has. Elaiapharm (Nice, France) went through receivership and is now owned by the Danish pharmaceutical company Lundbeck.

This is not to say that there will be no pharma-to-CMO/CRO deals in the near future. There are often good strategic reasons to complete these transactions, including filling a hole in a company's service offerings or extending a strategic relationship with a key client. In fact, in several recent deals, companies were able to achieve both of these objectives simultaneously. When Covance (Princeton, NJ) acquired Eli Lilly's (Indianapolis, IN) site in Greenfield, Indiana, it gained a 10-year services contract and some critical discovery-related technologies. Similarly, in its recent acquisition of the R&D site in Verona, Italy, from GlaxoSmithKline (London), Aptuit (Greenwich) gained discovery capabilities while enhancing a key client relationship.

These deals show that a bargain price is no longer an adequate incentive for acquiring a redundant facility from a major bio/pharmaceutical company. There must be a strong strategic rationale and an adequate revenue stream for the facility to achieve standalone viability. Executives we spoke with say they have walked away from many offered facilities because the economics and strategic rationale were missing. The global bio/pharmaceutical companies may get offers from small and mid-sized bio/pharmaceutical companies for their redundant facilities, but CMOs and CROs are not lining up to buy them.

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here